[1]曹杨琳,杨剑峰,何杨.肠道微生物群在血栓形成及心脑血管疾病中的研究进展[J].现代检验医学杂志,2018,33(03):162-164.[doi:10.3969/j.issn.1671-7414.2018.03.042]
　CAO Yang-lin,YANG Jian-feng,HE Yang.Research Progress of Gut Microbiota in the Thrombosis Formation and Cerebro-Cardiovascular Disease[J].Journal of Modern Laboratory Medicine,2018,33(03):162-164.[doi:10.3969/j.issn.1671-7414.2018.03.042]
点击复制

肠道微生物群在血栓形成及心脑血管疾病中的研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年03期
页码:
162-164
栏目:
综述
出版日期:
2018-07-17

文章信息/Info

Title:
Research Progress of Gut Microbiota in the Thrombosis Formation and Cerebro-Cardiovascular Disease
文章编号:
1671-7414(2018)03-162-03
作者:
曹杨琳; 杨剑峰; 何杨
苏州大学附属第一医院,江苏省血液研究所,江苏苏州 215006
Author(s):
CAO Yang-lin; YANG Jian-feng; HE Yang
the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology,Jiangsu Suzhou 215006,China
关键词:
心脑血管病;  肠道微生物群;  血小板;  血栓
分类号:
R54; R446.5
DOI:
10.3969/j.issn.1671-7414.2018.03.042
文献标志码:
A
摘要:
心脑血管疾病作为临床常见病,具有高发病率、高致残率及高死亡率的特点。研究认为血小板黏附、活化及聚集引起的血管内血栓是导致心脑血管疾病发生的重要原因之一,因此,探索和明确有关血小板活化及血栓形成的因素是预防和控制心脑血管疾病的重要切入点。最近的研究显示肠道微生物群作为人体内最大最复杂的微生态系统参与到血小板功能的调控中。笔者对肠道微生物群参与血栓形成及作为血栓性疾病治疗手段的最新进展进行综述,从而为肠道微生物群为基础的治疗方案在心脑血管疾病中的临床应用提供新的思路和理论依据。
Abstract:
Abstract:Cerebro-cardiovascular disease which is commonin clinical practice is featured by its high incidence,morbidity and mortality.So studies have shown that adhesion,activation and aggregation of the platelets and thrombosis induced by platelets are considered to play a critical role inthe pathogenesis of cerebro-cardiovascular disease,therefore,exploration andidentification of the factors involved in the platelet activation and thrombosis formation is an important incision for prevention and control of cerebro-cardiovascular disease.Recent studies have suggested that gut microbiota,as the most largest and complicated micro-ecosystem in human body,is participated in the platelet function regulation.Here,author reviewed the recent progress aboutthe role of gut microbiota in thrombosis formation and its therapeutic potential,and these data are believed to provide novel insight and theory basis for application of gut microbiota-base treatment regimen in the cerebro-cardiovasculardiseases.

参考文献/References:

[1] Peetermans M,Verhamme P,Vanassche T.Coagulase activity by Staphylococcus aureus:a potential target for therapy?[J].Seminars in Thrombosisand Hemostasis,2015,41(4):433-444.
[2] Wang Z,Roberts AB,Buffa JA,et al.Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis[J].Cell,2015,163(7):1585-1595.
[3] Zhu W,Gregory JC,Org E,et al.Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J].Cell,2016,165(1):111-124.
[4] Organ CL,Otsuka H,Bhushan S,et al.Choline diet and its gut microbe-derived metabolite,trimethylamine N-oxide,exacerbate pressure overload-induced heart failure[J].Circulation Heart Failure,2016,9(1):e002314.
[5] Tang WH,Wang Z,Levison BS,et al.Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J].The New England Journal of Medicine,2013,368(17):1575-1584.
[6] Falony G,Vieira-Silva S,Raes J.Microbiology meets big data:the caseof gut microbiota-derived trimethylamine[J].Annual Review of Microbiology,2015,69(1):305-321.
[7] Liu TX,Niu HT,Zhang SY.Intestinal microbiota metabolism and atherosclerosis[J].Chinese Medical Journal,2015,128(20):2805-2011.
[8] Tilg H.A gut feeling about thrombosis[J].The New England Journal of Medicine,2016,374(25):2494-2496.
[9] Spadoni I,Zagato E,Bertocchi A,et al.A gut-vascular barrier controlsthe systemic dissemination of bacteria[J].Science(New York,N Y),2015,350(6262):830-834.
[10] Yano JM,Yu K,Donaldson GP,et al.Indigenous bacteria from thegut microbiota regulate host serotonin biosynthesis[J].Cell,2015,161(2):264-276.
[11] Balmer ML,Slack E,de Gottardi A,et al.The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota[J].Science Translational Medicine,2014,6(237):237ra66.
[12] Jaeckel S,Kiouptsi K,Lillich M,et al.Gut microbiota regulate hepaticvon Willebrand factor synthesis and arterial thrombus formation via Toll-likereceptor-2[J].Blood,2017,130(4):542-553.
[13] Seaman CD,Yabes J,Comer DM,et al.Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register[J].Journal of Thrombosis and Haemostasis,2015,13(11):1999-2003.
[14] Verhenne S,Denorme F,Libbrecht S,et al.Platelet-derived VWF is notessential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice[J].Blood,2015,126(14):1715-1722.
[15] Nightingale T,Cutler D.The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story[J].Journal of Thrombosis and Haemostasis,2013,11(Suppl 1):192-201.
[16] Biswas S,Xin L,Panigrahi S,et al.Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic ApoE-/- mice and activateplatelets via TLR2[J].Blood,2016,127(21):2618-2629.
[17] Rivadeneyra L,Carestia A,Etulain J,et al.Regulation of platelet responses triggered by Toll-like receptor 2 and 4 ligands is another non-genomic role of nuclear factor-kappa B[J].Thrombosis Research,2014,133(2):235-243.
[18] Carnevale R,Raparelli V,Nocella C,et al.Gut-derived endotoxin stimulates factor Ⅷ secretion from endothelial cells.Implications for hypercoagulability in cirrhosis[J].Journal of Hepatology,2017,67(5):950-956.
[19] Pan J,Dinh TT,Rajaraman A,et al.Patterns of expression of factor Ⅷand von Willebrand factor by endothelial cell subsets in vivo[J].Blood,2016,128(1):104-109.
[20] Angelberger S,Reinisch W,Makristathis A,et al.Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation[J].The American Journal of Gastroenterology,2013,108(10):1620-1630.

相似文献/References:

[1]蒋燕成,陈辉华,陈雅斌,等.中国福建泉州地区心脑血管患者 CYP2C19，ABCB1基因多态性的检测分析[J].现代检验医学杂志,2019,34(06):10.[doi:10.3969 ／ j.issn.1671-7414.2019.06.003]
　JIANG Yan-cheng,CHEN Hui-hua,CHEN Ya-bin,et al.Detection and Analysis of CYP2C19 and ABCB1 Gene Polymorphism in Patients with Cardiovascular and Cerebrovascular Diseases in Quanzhou of Fujian, China[J].Journal of Modern Laboratory Medicine,2019,34(03):10.[doi:10.3969 ／ j.issn.1671-7414.2019.06.003]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81773356,81673096,81700129),江苏省自然科学基金(BK20171204)。 作者简介:曹杨琳(1994-),女,在读研究生,研究方向:临床检验与诊断学,E-mail:cyl1010012@163.com。 通讯作者:何 杨,E-mail:heyang1963@163.com。
更新日期/Last Update: 2018-04-16